Tumor necrosis factor-α blockade for the treatment of acute GVHD

Blood

Volumn 104, Issue 3, 2004, Pages 649-654

  Couriel, Daniel ^a   Saliba, Rima ^b   Hicks, Krystal ^b   Ippoliti, Cindy ^b   De Lima, Marcos ^b   Hosing, Chitra ^b   Khouri, Issa ^b   Andersson, Borje ^b   Gajewski, James ^b   Donato, Michele ^b   Anderlini, Paolo ^b   Kontoyiannis, Dimitrios P ^b   Cohen, Agueda ^b   Martin, Thomas ^b   Giralt, Sergio ^b   Champlin, Richard ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIBODY; IMMUNOGLOBULIN G1; INFLIXIMAB; METHYLPREDNISOLONE; PROTEIN SUBUNIT; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; ASPERGILLUS; BACTERIAL INFECTION; CANCER PATIENT; CANDIDA; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG MECHANISM; FEMALE; GASTROINTESTINAL TRACT; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MALE; MEMBRANE BINDING; MYCOSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 3242756749     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-12-4241     Document Type: Article

References (54)

1. Gajewski J, Champlin R. Bone marrow transplantation from unrelated donors. Curr Opin Oncol. 1996;8:84-88.
2. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-versus-host disease: pathobiology and management. Exp Hematol. 2001;29:259-277.
3. Basara N, Kiehl MG, Fauser AA. New therapeutic modalities in the treatment of graft-versus-host disease. Crit Rev in Onc/Hematol 2001;38:129-138.
4. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med. 1993;329:1225-1230.
5. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324;667-674.
6. Chao NJ. Graft-versus-host disease: the view-point from the donor T cell. Biol Blood Marrow Transplant. 1997;3:1-10.
7. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-versus-host disease. Biol Bone Marrow Transplant. 1999;5:347-356.
8. Blazar BR, Taylor PA, Panoskaltis-Mortari A, et al. Coblockade of the LFA-1/ICAM and CD28/CTL4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully MHC-disparate donor grafts. Blood. 1995;85:2607-2618.
9. Rus V, Svetic A, Nguyen P, et al. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease: regulatory role of donor CD8+ T cells. J Immunol. 1995;155:2396-2406.
10. Graubert TA, Rusell JH, Ley TJ. The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood. 1996;87:1232-1237.
11. Vandenabeele P, Declrecq W, Vanhaesebroeck B, et al. Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J Immunol. 1995;154:2904-2913.
12. Vassalli P, Grau GE, Piguet PF, et al. TNF in autoimmune diseases, graft-versus-host reactions, and pulmonary fibrosis. Immunol Ser. 1992;56:409-430.
13. Wallach D. Cell death induction by TNF: a matter of self-control. Trends Biochem Sci. 1997;22:107-109.
14. Couriel DR, Hicks K, Giralt S, et al. Role of tumor necrosis factor-alpha inhibition with infliximab in cancer therapy and hematopoietic stem cell transplantation. Curr Op Oncol. 2000;12:582-587.
15. Ferrara JL. The cytokine modulation of acute graft-versus-host disease. Bone Marrow Transplant. 1998;21(suppl 3):S13-S15.
16. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011-1016.
17. Remberger M, Ringden O, Markling L. TNF-alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant. 1995;15:99-104.
18. Scallon BJ, Moore AM, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251-259.
19. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis, Drugs. 2000;59:1341-1359.
20. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999, 340:1398-1405.
21. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease: Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
22. Lang KA, Peppercorn MA. Promising new agents for the treatment of inflammatory bowel disorders. Drugs R D. 1999;1:237-244.
23. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med. 2000;51:207-229.
24. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000;43:1346-1352.
25. Oh CJ, Das KM, Gottlieb AB. Treatment with antitumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000;42:829-830.
26. Redei I, Knoche J, Tanner AR, et al. Salvage therapy with infliximab for patients with severe acute and chronic GVHD [abstract]. Blood. 2001;98:399.
27. Magalhaes-Silverman M, Lee CK, Hohl R, et al. Treatment of severe steroid refractory acute graft versus host disease with infliximab [abstract]. Blood. 2001;98:5208.
28. Kobbe G, Schneider P, Rohr U, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNF alpha antibody. Bone Marrow Transplant. 2001;28:47-49.
29. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
30. Cornfield J, Gordon T, Smith WW. Quantal response curves for experimentally uncontrolled variables. Bull Int Stat Inst. 1961;38:97-115.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
32. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc Series B. 1972;34:187-220.
33. Lazarus HM, Vogelsang GB, Rowe JM. Prevention of acute graft-versus-host disease: the old and the new: a report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant. 1997;19:577-560.
34. Martin PJ, Nelson BJ, Appelbaum FR, et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood. 1996, 88:824-830.
35. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75:1024-1030.
36. Roy J, McGlave PB, Filipovich AH, et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant. 1992;10:77-82.
37. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464-1472.
38. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood. 1991;77:1821-1828.
39. Jacobson P, Uberti J, Davis W, et al. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant. 1998;22:217-225.
40. Basara N, Blau WI, Kiehl MG, et al. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Transplant Proc. 1998;30:4087-4089.
41. Basara N, Kiehl MG, Blau W, et al. Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplant Proc. 2001;33:2121-2123.
42. Benito AI, Furlong T, Martin PJ, et al. Sirolimus (Rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation. 2001;72:1924-1929.
43. Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000;95:83-89.
44. Willenbacher W, Basara N, Blau IW, et al. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol. 2001;112:820-823.
45. Basara N, Günzelmann S, Willenbacher W, et al. New immunosuppressants in BMT/GVHD. Transplant Proc. 2001;33:2220-2222.
46. Pasquini R, Moreira VA, de Medeiros CA, et al. Basiliximab (BaMab), a selective interleukin-2 receptor antagonist as therapy for refractory acute graft versus host disease following bone marrow transplantation [abstract]. Blood. 2000;9611:117.
47. Przepiorka D, Phillips GL, Ratanatharathorn V, et al. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood. 1998;9211:2066-2071.
48. Carpenter PA, Appelbaum FR, Corey L, et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood. 2002;99:2712-2719.
49. Martin PJ, Nelson BJ, Appelbaum FR, et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood. 1996;88:824-830.
50. Deeg HJ, Blazar BR, Bolwell BJ, et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood. 2001;98:2052-2058.
51. Marty F, Lee S, Fahey M, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood. 2003;102:2768-2776.
52. Fukuda T, Boeckh M, Carter R, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloabiative conditioning. Blood. 2003;102:827-833.
53. Baden LR. Prevention and therapy of fungal infections in bone marrow transplantation. Leukemia. 2003;17:1038-1041.
54. Baddley J, Stroud T, Salzman D. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis. 2001;32:1319-1324.